{"id":"itcz-oral-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Itraconazole binds to fungal CYP51 enzyme, blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and cell death. The oral solution formulation enhances bioavailability compared to capsule formulations, particularly in patients with achlorhydria or those taking acid-suppressing medications.","oneSentence":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:24.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oropharyngeal candidiasis"},{"name":"Esophageal candidiasis"},{"name":"Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)"}]},"trialDetails":[{"nctId":"NCT00784368","phase":"PHASE3","title":"A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-01","conditions":"Mycoses, Candidiasis, Aspergillosis","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Itrizole Oral Solution 1%, JK1211"],"phase":"phase_3","status":"active","brandName":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Oropharyngeal candidiasis, Esophageal candidiasis, Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}